Actively Recruiting
Evaluating Safety, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adults with Advanced Lung and Breast Cancer
Led by Bristol-Myers Squibb · Updated on 2026-09-23
416
Participants Needed
65
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, tolerability, drug levels, and early effectiveness of combinations involving BMS-986507 in adults with advanced solid tumors, including lung and breast cancer. This phase 12a open-label trial aims to find the right dose and assess how these drug combinations behave in the body. Participants will receive BMS-986507 combined with other drugs such as Osimertinib, Pembrolizumab, Nivolumab, or Pumitamig at specified doses and schedules. The study includes several groups based on cancer type and genetic mutations. The treatment period and dose evaluation last up to 3 years, with a special focus on dose-limiting toxicity within the first 3 weeks. During the trial, participants will be monitored for side effects, serious adverse events, and drug-related toxicities. Researchers will measure drug levels in the blood over time and evaluate tumor response. The study involves regular visits for assessments, safety monitoring, and data collection over the treatment and follow-up periods, which can last up to 3 years after starting treatment.
CONDITIONS
Brief Title
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here